Sulforaphane-mediated reduction of aflatoxin B₁-N⁷-guanine in rat liver DNA: impacts of strain and sex
- PMID: 21278056
- PMCID: PMC3080186
- DOI: 10.1093/toxsci/kfr026
Sulforaphane-mediated reduction of aflatoxin B₁-N⁷-guanine in rat liver DNA: impacts of strain and sex
Abstract
Aflatoxin B₁ (AFB₁) is a DNA-binding toxin that contributes to the burden of liver cancer in tropical areas. AFB₁-DNA adducts are powerful biomarkers that discern individual and population risk from exposure to this carcinogen. The discovery of concordance between the metabolic pathways of the male Fischer rat and humans allowed data from rats to guide the development of chemoprevention strategies employed in clinical trials in high-risk regions. In this study, the variables of strain and sex are studied in the rat model, as a step toward understanding how ethnic differences and sex influence DNA adduct formation and the induction of enzymes by chemoprotective agents. Sulforaphane (SF), which induces phase II enzymes including glutathione S-transferases (GSTs), was evaluated for its ability to induce GST activity and reduce the AFB₁-DNA adducts in livers of both sexes of two rat strains that differ in susceptibility to AFB₁ hepatocarcinogenesis. A dose-dependent relationship was found for SF for both induction of GST and reduction in of AFB₁-N⁷-guanine in both Fischer (sensitive to AFB₁) and Sprague-Dawley rats (relatively resistant). Sprague-Dawley rats exhibited the greatest increase in GST levels and the largest reduction in AFB₁-N⁷-guanine in liver DNA. Males and females of each strain were also compared to determine if the ability of SF to induce GST and reduce AFB₁-N⁷-guanine correlated with gender differences in sensitivity to AFB₁ carcinogenesis. No gender-specific responses to SF were observed. These results support the view that SF induction of liver GST activity may play a role in its chemoprotective activity.
Figures



Similar articles
-
Susceptibility to aflatoxin B1-induced carcinogenesis correlates with tissue-specific differences in DNA repair activity in mouse and in rat.Cancer Res. 2005 Feb 15;65(4):1265-70. doi: 10.1158/0008-5472.CAN-04-3373. Cancer Res. 2005. PMID: 15735011
-
Oltipraz-mediated changes in aflatoxin B(1) biotransformation in rat liver: implications for human chemointervention.Cancer Res. 1996 May 15;56(10):2306-13. Cancer Res. 1996. PMID: 8625305
-
Dissimilarity in aflatoxin dose-response relationships between DNA adduct formation and development of preneoplastic foci in rat liver.Chem Biol Interact. 1997 Oct 24;106(3):213-27. doi: 10.1016/s0009-2797(97)00078-1. Chem Biol Interact. 1997. PMID: 9413548
-
Interindividual differences in response to chemoprotection against aflatoxin-induced hepatocarcinogenesis: implications for human biotransformation enzyme polymorphisms.Adv Exp Med Biol. 2001;500:559-76. doi: 10.1007/978-1-4615-0667-6_85. Adv Exp Med Biol. 2001. PMID: 11764998 Review.
-
Dietary modulation of the biotransformation and genotoxicity of aflatoxin B(1).Toxicology. 2012 Sep 28;299(2-3):69-79. doi: 10.1016/j.tox.2012.05.016. Epub 2012 May 26. Toxicology. 2012. PMID: 22640941 Review.
Cited by
-
Interaction of DNA repair gene polymorphisms and aflatoxin B1 in the risk of hepatocellular carcinoma.Int J Clin Exp Pathol. 2014 Aug 15;7(9):6231-44. eCollection 2014. Int J Clin Exp Pathol. 2014. PMID: 25337275 Free PMC article.
-
Sulforaphane, a cancer chemopreventive agent, induces pathways associated with membrane biosynthesis in response to tissue damage by aflatoxin B1.Toxicol Appl Pharmacol. 2015 Jan 1;282(1):52-60. doi: 10.1016/j.taap.2014.11.004. Epub 2014 Nov 18. Toxicol Appl Pharmacol. 2015. PMID: 25450479 Free PMC article.
-
Formation of DNA Adducts by 1-Methoxy-3-indolylmethylalcohol, a Breakdown Product of a Glucosinolate, in the Mouse: Impact of the SULT1A1 Status-Wild-Type, Knockout or Humanised.Int J Mol Sci. 2024 Mar 29;25(7):3824. doi: 10.3390/ijms25073824. Int J Mol Sci. 2024. PMID: 38612635 Free PMC article.
-
Pharmacokinetics and pharmacodynamics of 3,3'-diindolylmethane (DIM) in regulating gene expression of phase II drug metabolizing enzymes.J Pharmacokinet Pharmacodyn. 2015 Aug;42(4):401-8. doi: 10.1007/s10928-015-9421-5. Epub 2015 Jul 3. J Pharmacokinet Pharmacodyn. 2015. PMID: 26138223
-
Modulation of protein quality control systems by food phytochemicals.J Clin Biochem Nutr. 2013 May;52(3):215-27. doi: 10.3164/jcbn.12-126. Epub 2013 Mar 20. J Clin Biochem Nutr. 2013. PMID: 23704811 Free PMC article.
References
-
- Busby WF, Wogan GN. Aflatoxins. In: Searle CD, editor. Chemical Carcinogens. Washington, DC: American Chemical Society; 1984. pp. 945–1136.
-
- Dinkova-Kostova AT, Holtzclaw WD, Kensler TW. The role of Keap1 in cellular protective responses. Chem. Res. Toxicol. 2005;18:1779–1791. - PubMed
-
- Egner PA, Gange SJ, Dolan PM, Groopman JD, Muñoz A, Kensler TW. Levels of aflatoxin-albumin biomarkers in rat plasma are modulated by both long-term and transient interventions with oltipraz. Carcinogenesis. 1995;16:1769–1773. - PubMed
-
- Egner PA, Groopman JD, Wang JS, Kensler TW, Friesen MD. Quantification of aflatoxin-B1-N7-Guanine in human urine by high-performance liquid chromatography and isotope dilution tandem mass spectrometry. Chem. Res. Toxicol. 2006;19:1191–1195. - PubMed
-
- Fahey JW, Haristoy X, Dolan PM, Kensler TW, Scholtus I, Stephenson KK, Talalay P, Lozniewski A. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc. Natl. Acad. Sci. U.S.A. 2002;99:7610–7615. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials